Done Safety, Regulation & Compliance Posture: An Independent Clinical Review

What Is Done and How Does It Operate?

Done launched in 2019 as a direct-to-consumer telehealth platform specializing in ADHD assessment and medication management. The company's model is simple: patients complete an online questionnaire, schedule a video visit with a clinician, and may receive a stimulant prescription the same day. Monthly subscription fees cover follow-up appointments and prescription renewals.

This cash-pay model bypasses insurance credentialing entirely. That removes prior authorization delays but also strips away a layer of external utilization review that traditional prescribers face when writing Schedule II controlled substance prescriptions. The National Institute of Mental Health estimates adult ADHD prevalence at 4.4% in the United States [1], and the CDC reported that stimulant prescription fills among adults aged 20 to 39 rose 10.4% between 2020 and 2021 alone [2]. Done entered a market of genuine unmet demand. The question is whether its clinical processes matched the seriousness of the medications it dispensed.

ADHD is a real, impairing condition. A 2021 international consensus statement published in Neuroscience & Biobehavioral Reviews and endorsed by 80 researchers confirmed strong evidence for neurobiological underpinnings and treatment efficacy [3]. But proper diagnosis requires more than a brief questionnaire. The American Academy of Family Physicians recommends structured interviews, collateral history, and ruling out mood disorders, sleep disorders, and substance use before prescribing stimulants [4].

The Federal Indictment: What Happened

In 2024, the U.S. Department of Justice indicted Done's CEO and its clinical president on charges of conspiracy to commit healthcare fraud and distributing controlled substances. The indictment alleged that Done's business model incentivized clinicians to prescribe stimulants to patients who did not meet diagnostic criteria for ADHD, generating revenue through subscription renewals tied to ongoing prescriptions.

This was not an isolated complaint. The charges described systemic issues: pressure on providers to keep appointments short, resistance to denying prescriptions, and inadequate clinical documentation. Federal prosecutors alleged that Done's operations resulted in over 40 million pills of Adderall and other stimulants being prescribed over the company's first few years of operation.

Pharmacies noticed. CVS, Walmart, and other major chains began flagging or outright refusing to fill prescriptions from Done clinicians, citing concerns about prescribing patterns. When pharmacists use their "corresponding responsibility" under the Controlled Substances Act to refuse a prescription, that signals a significant departure from standard prescribing norms [5]. A single pharmacy refusal might reflect a misunderstanding. Widespread refusals across multiple chains indicate a pattern.

The New England Journal of Medicine has noted that stimulant medications carry real cardiovascular and psychiatric risks, including increased heart rate, blood pressure elevation, and potential for psychotic symptoms at high doses [6]. These risks make thorough pre-prescribing evaluation a clinical necessity, not a bureaucratic formality.

Prescribing Practices Under Scrutiny

The core regulatory concern with Done centers on diagnostic rigor. A proper adult ADHD evaluation typically involves 60 to 90 minutes of structured assessment. The Lancet's 2020 ADHD seminar describes the gold standard as including developmental history, symptom rating scales, functional impairment assessment, and screening for comorbid conditions [7].

Reports from former Done patients and clinicians describe initial evaluations lasting 30 minutes or less, with limited follow-up questioning. Some clinicians reported feeling pressured to diagnose and prescribe within a single visit regardless of clinical uncertainty.

This matters because ADHD symptoms overlap with several other conditions. Anxiety produces concentration problems. Depression causes executive dysfunction. Sleep deprivation mimics ADHD almost perfectly. A 2018 meta-analysis in The Lancet Psychiatry evaluating 133 randomized trials found that while stimulants are effective for confirmed ADHD, they carry risk-benefit tradeoffs that demand accurate diagnosis first [8]. Prescribing amphetamine to a patient whose inattention stems from untreated insomnia does not treat their problem. It creates a new one.

The DEA's post-pandemic telehealth prescribing framework, finalized in 2025, now requires that patients receiving ongoing Schedule II controlled substance prescriptions via telehealth must complete an in-person evaluation within a specified timeframe. This rule emerged partly in response to the rapid expansion of platforms like Done that prescribed controlled substances entirely through video visits with no in-person component [5].

Pharmacy Refusals and Patient Impact

Patients caught in Done's compliance failures faced real consequences. Prescription refusals at the pharmacy counter left patients without medication they may have come to depend on, sometimes with no warning and no established relationship with a local psychiatrist who could bridge the gap.

The FDA's drug safety communications on stimulant medications emphasize that abrupt discontinuation after regular use can produce withdrawal symptoms including fatigue, depression, and sleep disturbance [9]. Patients who built treatment plans around Done's prescriptions found themselves medically vulnerable when pharmacies refused to fill.

This dynamic illustrates a broader problem with cash-pay telehealth models that operate outside insurance networks. Insurance-based prescribing creates friction, but it also creates documentation trails, prior authorization checks, and pharmacist-prescriber communication channels. When a platform bypasses all of these mechanisms simultaneously, the patient bears the risk if the system fails.

The CDC has documented that stimulant-related emergency department visits among adults increased during the same period that telehealth ADHD prescribing expanded most rapidly [2]. Correlation does not prove causation. But the timing warrants caution about any platform that streamlines access to Schedule II substances without proportionally strengthening clinical safeguards.

How to Evaluate Any Telehealth ADHD Provider

Not all telehealth ADHD services carry the same risk profile. Patients considering any remote ADHD platform should assess five clinical safeguards before enrolling:

1. Evaluation length and structure. The initial diagnostic appointment should last at least 60 minutes and include validated rating scales (such as the ASRS-v1.1 or DIVA-5), developmental history, and screening for comorbid conditions. Any provider offering same-day diagnosis in under 30 minutes is cutting clinical corners.

2. Willingness to say no. A legitimate ADHD provider will decline to prescribe stimulants when the clinical picture is unclear. Ask directly: "What percentage of your patients receive a non-stimulant recommendation or a referral for further testing?" If the answer is vague or close to zero, that is a red flag.

3. Pharmacy acceptance. Before paying for an evaluation, call your preferred pharmacy and ask whether they currently fill prescriptions from that telehealth platform. Widespread pharmacy refusals are a market signal about prescribing quality that patients can verify in advance.

4. Prescriber credentials. Board-certified psychiatrists and psychiatric nurse practitioners with ADHD-specific training represent the standard of care. The AAFP notes that primary care physicians prescribe the majority of adult ADHD medications, but complex cases benefit from specialist evaluation [4].

5. In-person follow-up pathway. Under current DEA telehealth rules, ongoing Schedule II prescriptions require an in-person evaluation. Any platform that lacks a clear pathway for this requirement may leave patients stranded when regulations are enforced.

Done vs. Alternative ADHD Telehealth Platforms

Done is not the only telehealth option for ADHD, and comparing platforms reveals meaningful differences in clinical safeguards.

Cerebral faced its own scrutiny after a 2022 investigation into prescribing practices, but the company subsequently restructured its clinical protocols, added longer evaluation times, and implemented a medical board with independent oversight. Cerebral also accepted insurance, which introduced external utilization review.

Talkiatry operates with board-certified psychiatrists who accept insurance, conduct 60-minute initial evaluations, and maintain traditional medical records. The platform functions more like a traditional psychiatric practice delivered via telehealth than a startup optimizing for prescription volume.

Traditional psychiatry with telehealth options remains the most conservative approach. Many academic medical centers and private practices now offer video visits for established patients, combining the convenience of telehealth with the diagnostic rigor of in-person initial evaluations.

A 2018 systematic review in JAMA Network Open found that ADHD diagnosis rates among children increased substantially over two decades, with variations that correlated more with access patterns than with true prevalence changes [10]. The same access-driven diagnostic inflation risk applies to adults when telehealth removes traditional barriers without maintaining clinical standards.

The difference between Done and more conservative platforms is not whether telehealth can serve ADHD patients well. It can. The difference is whether the platform treats controlled substance prescribing as a revenue-generating feature or as a clinical decision requiring proportional safeguards.

What Does Done Actually Prescribe?

Done's prescribing patterns center on Schedule II stimulants: mixed amphetamine salts (Adderall), lisdexamfetamine (Vyvanse), and methylphenidate (Ritalin, Concerta). These medications have strong evidence for efficacy in confirmed ADHD. The Lancet Psychiatry's 2018 network meta-analysis of 133 trials involving 10,068 children and 8,131 adults found amphetamines to be the most effective pharmacotherapy for adult ADHD based on clinician-rated symptom reduction [8].

Efficacy is not the issue. The issue is patient selection. The FDA's prescribing information for amphetamine-based stimulants carries a boxed warning for high abuse potential and notes contraindications including cardiovascular disease, hyperthyroidism, and history of substance use disorder [9]. These contraindications require screening that a 30-minute video visit may not adequately capture.

Non-stimulant alternatives exist. Atomoxetine (Strattera), guanfacine extended-release (Intuniv), and viloxazine (Qelbree) offer lower abuse potential, though with generally smaller effect sizes. A platform that defaults almost exclusively to stimulants without trialing or at least discussing non-stimulant options is not practicing guideline-concordant care. The AAFP's clinical guidance recommends discussing both stimulant and non-stimulant options with patients and tailoring the choice to individual risk factors [4].

The Broader Regulatory Environment for Telehealth Stimulant Prescribing

Done's legal troubles exist within a larger regulatory shift. During the COVID-19 public health emergency, the DEA suspended its requirement for in-person evaluations before prescribing controlled substances via telehealth. This temporary flexibility, originally meant to maintain care continuity during lockdowns, enabled rapid growth of platforms that had no in-person infrastructure at all.

The DEA's 2025 final rule re-established guardrails. Clinicians may now initiate a 30-day supply of a Schedule II controlled substance via telehealth, but continuing prescriptions requires either an in-person visit or a referral from a provider who has examined the patient in person [5]. This rule directly affects Done's operating model.

State-level enforcement adds another layer. Multiple state medical boards have opened investigations into telehealth prescribing patterns for controlled substances. The Federation of State Medical Boards issued guidance in 2023 emphasizing that telehealth prescribers must meet the same standard of care as in-person providers, including documentation requirements and informed consent for controlled substance risks [5].

For patients, the practical implication is clear. Any telehealth ADHD provider that cannot articulate how it complies with current DEA telehealth prescribing rules is operating in a regulatory gray zone that may leave patients without medication access when enforcement actions occur.

Is Done Legit?

Done is a real, registered company that employs licensed clinicians. That baseline legitimacy, however, does not address the specific compliance failures that led to federal criminal charges against its leadership. A platform can be legally incorporated and still operate in ways that violate prescribing standards.

The most useful framework for patients is not "is this company real?" but rather "does this company's clinical model match the standard of care for the condition it treats?" For ADHD, the standard of care involves thorough diagnostic evaluation, consideration of comorbidities, discussion of both stimulant and non-stimulant options, cardiovascular screening before prescribing stimulants, and ongoing monitoring with dose adjustments based on response and tolerability [6][7].

Patients who already receive care through Done should not panic or abruptly stop medication. The safest transition involves establishing care with a local psychiatrist or a more structured telehealth provider who can review existing records and continue appropriate treatment without interruption. The FDA warns that abrupt stimulant discontinuation after chronic use may cause rebound symptoms [9], so any medication changes should be medically supervised.

Adults with ADHD who suspect they may benefit from treatment should seek providers who spend at least 60 minutes on initial evaluation, screen for comorbid anxiety, depression, and sleep disorders, and discuss the full range of pharmacologic and behavioral treatment options before writing a prescription for Schedule II stimulants.